| 彭柳.中风通脉汤联合瑞舒伐他汀治疗急性脑梗死患者的临床疗效观察[J].浙江中西医结合杂志,2026,36(6): |
| 中风通脉汤联合瑞舒伐他汀治疗急性脑梗死患者的临床疗效观察 |
|
| 投稿时间：2025-05-30 修订日期：2026-05-12 |
| DOI： |
| 中文关键词: 急性脑梗死 中风通脉汤 瑞舒伐他汀 临床疗效 |
| 英文关键词:acute cerebral infarction Stroke Tongmai Decoction Rosuvastatin Clinical effect |
| 基金项目: |
|
| 摘要点击次数: 64 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨中风通脉汤联合瑞舒伐他汀治疗急性脑梗死(AIS)患者的临床疗效。方法? 选取2022年6月-2023年5月在商丘市中医院接受治疗的80例AIS患者,运用随机信封法将研究对象划分为单药组和联合组两组,每组各40例。单药组给予基础治疗和瑞舒伐他汀,联合组给予基础治疗、瑞舒伐他汀和中风通脉汤治疗,比较两组治疗前及治疗10 d后中医证候积分、计算机断层灌注成像(CTPI)参数、血液流变学指标、神经细胞因子和凝血功能指标。结果? 治疗10 d后,两组中医证候积分、梗死核心区和缺血半暗带区平均通过时间(MTT)、全血高切黏度(HBV)、红细胞聚集指数(EAI)、红细胞沉降率(ESR)、神经元特异性烯醇化酶(NSE)、纤维蛋白原(FIB)均较治疗前降低(P＜0.05),联合组低于单药组(P＜0.05),梗死核心区和缺血半暗带区脑血容量(CBV)、脑血流量(CBF)、神经营养因子(NTF)和神经生长因子(NGF)较治疗前升高(P＜0.05),联合组高于单药组(P＜0.05)；治疗10 d后,两组凝血酶原时间(PT)和凝血酶时间(TT)比较,差异无统计学意义(P＞0.05)。结论? 中风通脉汤联合瑞舒伐他汀在AIS患者中展现出良好临床疗效,能够显著改善梗死核心区和缺血半暗带区脑灌注以及血液流变学,减少神经损伤。 |
| 英文摘要: |
| Objective: To investigate the clinical efficacy of stroke Tongmai Decoction combined with Rosuvastatin in the treatment of acute cerebral infarction. Methods: A total of 80 AIS patients treated in Shangqiu Hospital of Traditional Chinese Medicine from June 2022 to May 2023 were selected, and the study subjects were divided into two groups by random envelope method, with 40 cases in each group. The monotherapy group was given basic treatment and rosuvastatin, and the combination group was given basic treatment, rosuvastatin and stroke Tongmai Decoction. TCM syndrome scores, computed tomographic perfusion imaging (CTPI) parameters, hemorheology indexes, nerve cytokines and coagulation function indexes were compared between the two groups before and 10 days after treatment. Result: After 10 days of treatment, TCM syndrome score, mean transit time (MTT), whole blood high tangency viscosity (HBV), red blood cell aggregation index (EAI), erythrocyte sedimentation rate (ESR), neuronal specific enolase (NSE) and fibrinogen (FIB) in both groups were decreased compared with those before treatment (P < 0.05). Combined group was lower than monotherapy group (P < 0.05), cerebral blood volume (CBV), cerebral blood flow (CBF), neurotrophic factor (NTF) and nerve growth factor (NGF) in infarction core area and ischemic penumbra area were higher than before treatment (P < 0.05), and combined group was higher than monotherapy group (P < 0.05). The combination group was compared with the monotherapy group, there were no statistically significant differences in prothrombin time (PT) and thrombin time (TT) after 10 days of treatment. Conclusion: Zhongfengtongmai Decoction combined with Rosuvastatin showed a good clinical effect in patients with acute cerebral infarction, which can significantly improve cerebral perfusion and hemorheology in the core area of infarction and ischemic penumbra area, and reduce nerve injury. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
